Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Monday. The brokerage currently has a $4.25 target price on the biopharmaceutical company’s stock. Zacks Investment Research‘s price objective would suggest a potential upside of 10.82% from the stock’s previous close.

According to Zacks, “Achillion generated no revenue in Q3 while loss was narrower than the estimates. The company has no approved product in its portfolio and focuses on developing small molecule therapeutics to treat infectious and complement-mediated diseases. Meanwhile, the company has shown progress in developing Factor D inhibitors. The lead candidate, ACH-4471 has shown clinically meaningful complement inhibition of factor D in PNH patients. Meanwhile, another factor D inhibitor candidate will be advanced to phase I study this year. Though this area has commercial opportunity the complement-mediated space is highly crowded as many biotech companies are working on bringing these treatments to market. In a major setback, J&J terminated its HCV agreement in September and Achillion lost a strong and experienced partner and source of funds. Meanwhile, shares have underperformed the industry so far this year.”

A number of other brokerages also recently issued reports on ACHN. BidaskClub downgraded Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, July 25th. Ladenburg Thalmann Financial Services reduced their price target on Achillion Pharmaceuticals from $9.00 to $6.50 and set a “buy” rating on the stock in a report on Tuesday, September 12th. Maxim Group set a $7.00 price target on Achillion Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 9th. Chardan Capital restated a “neutral” rating on shares of Achillion Pharmaceuticals in a report on Sunday, September 17th. Finally, Robert W. Baird downgraded Achillion Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $5.00 price target on the stock. in a report on Thursday, August 10th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company’s stock. Achillion Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $5.29.

Achillion Pharmaceuticals (NASDAQ:ACHN) traded down $0.06 on Monday, hitting $3.84. The stock had a trading volume of 178,059 shares, compared to its average volume of 1,569,971. Achillion Pharmaceuticals has a 1 year low of $3.15 and a 1 year high of $5.66.

Achillion Pharmaceuticals (NASDAQ:ACHN) last released its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.14) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.04. During the same period in the previous year, the company posted ($0.15) earnings per share. research analysts expect that Achillion Pharmaceuticals will post -0.63 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This article was posted by Watch List News and is owned by of Watch List News. If you are reading this article on another site, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this article can be viewed at

A number of institutional investors have recently bought and sold shares of ACHN. Janus Henderson Group PLC bought a new stake in Achillion Pharmaceuticals during the 2nd quarter valued at approximately $20,778,000. Dimensional Fund Advisors LP boosted its position in Achillion Pharmaceuticals by 75.3% during the 3rd quarter. Dimensional Fund Advisors LP now owns 3,276,076 shares of the biopharmaceutical company’s stock valued at $14,710,000 after acquiring an additional 1,407,108 shares in the last quarter. Senzar Asset Management LLC bought a new stake in Achillion Pharmaceuticals during the 2nd quarter valued at approximately $4,966,000. Artal Group S.A. bought a new stake in Achillion Pharmaceuticals during the 3rd quarter valued at approximately $4,490,000. Finally, EcoR1 Capital LLC bought a new stake in Achillion Pharmaceuticals during the 2nd quarter valued at approximately $3,410,000. 74.81% of the stock is currently owned by institutional investors and hedge funds.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Analyst Recommendations for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.